SLC39A6 and renal cell carcinoma: For example, some researchers treat renal cell carcinoma (RCC) with immune checkpoint inhibitors (ICIs) plus TKIs [5], while breast cancer is treated with ICIs plus ladiratuzumab (targeting LIV-1) [6].